Raloxifene
Raloxifene (Evista) is an osteoporosis tablet that also lowers the chance of developing invasive breast cancer in postmenopausal women at higher risk, with fewer womb-cancer problems than tamoxifen.
Overview
Raloxifene was approved in December 1997 for treatment and prevention of postmenopausal osteoporosis and in September 2007 for reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of breast cancer, on the MORE, CORE and RUTH trials and the head-to-head STAR trial (NSABP P-2), in which raloxifene was about as effective as tamoxifen against invasive breast cancer with fewer uterine cancers and thromboembolic events but less protection against non-invasive disease. It does not treat breast cancer or reduce recurrence. Venous thromboembolism and fatal stroke in women with coronary disease carry a boxed warning.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1997 | Treatment and prevention of postmenopausal osteoporosis |
| US | 2007 | Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Raloxifene" OR ABSTRACT:"Raloxifene" OR TITLE:"Evista" OR ABSTRACT:"Evista") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Raloxifene, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductToremifene
Shares Tamoxifen, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag nci-list.
- ProductAminolevulinic acid (topical, for photodynamic therapy)
Shares the tags nci-list, prevention.
- ProductHPV bivalent vaccine (types 16 and 18)
Shares the tags nci-list, prevention.
- ProductHPV quadrivalent vaccine (types 6, 11, 16 and 18)
Shares the tags nci-list, prevention.
- IdeaLow-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses
Shares Chemoprevention & risk-reducing surgery, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- PersonJack Cuzick
Shares Chemoprevention & risk-reducing surgery, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag prevention.
- ProductNecitumumab
Shares Eli Lilly (incl. Loxo) and the tag nci-list.
- ProductTriptorelin
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag nci-list.